Northwest Biotherapeutics (NWBO) Capital Expenditures Growth (3y) (2013 - 2026)
Northwest Biotherapeutics (NWBO) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 16.27% |
| 10 | Northwest Biotherapeutics | 277.19 Mn | 275.40 Mn | - | -54.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -54.09% |
| Dec 31, 2025 | -25.17% |
| Sep 30, 2025 | -9.88% |
| Jun 30, 2025 | -9.34% |
| Mar 31, 2025 | 17.04% |
| Dec 31, 2024 | -63.10% |
| Sep 30, 2024 | -59.71% |
| Jun 30, 2024 | -29.82% |
| Mar 31, 2024 | -3.26% |
| Dec 31, 2023 | -48.51% |
| Sep 30, 2023 | -42.02% |
| Jun 30, 2023 | 0.13% |
| Mar 31, 2023 | 178.06% |
| Dec 31, 2022 | 166.59% |
| Sep 30, 2022 | 135.99% |
| Jun 30, 2022 | 21.94% |
| Dec 31, 2020 | 700.17% |
| Sep 30, 2020 | 665.40% |
| Jun 30, 2020 | 417.04% |
| Dec 31, 2019 | -12.30% |